Leiden

• Single and multiple ascending dose of ZP9830 in healthy participants Recruiting
  2023-509929-51-00 1 2026-02-10 Autoimmune diseases
• A study on the safety, tolerability, and effectiveness of the new drug LAD106 in healthy volunteers. Recruiting
  2025-523328-31-00 1 2026-02-06 Inflammatory diseases
• SKIPP2: Cabozantinib Dose Skipping as an Alternative to Dose Reductions Recruiting
  2025-522962-58-00 4 2026-01-26 Renal cell carcinom
• IMCISION: Towards organ preservation and cure via ultra-short immunotherapy in advanced oral cancer. The IMCISION II trial, an investigator … Recruiting
  2025-522500-24-00 5 2026-01-20 Head and Neck squamous cell carcinoma
• A Study to Investigate ARV-027 in Healthy Male Participants and Participants with Spinal and Bulbar Muscular Atrophy Recruiting
  2025-523469-79-00 1 2026-01-16 Spinal and Bulbar Muscular Atrophy
• CO2MO Recruiting
  2025-520913-29-00 6 2026-01-14 Melanoma
• A Study to Learn About Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants Recruiting
  2022-503070-36-00 5 2025-12-23 Group B streptococcus (GBS) disease
• A study to investigate efficacy and safety of teplizumab compared with placebo in participants 1 to 25 years of age with Stage 3 Type 1 Diab … Recruiting
  2024-519494-19-00 5 2025-12-22 Nutritional and metabolic diseases
• A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting
  2025-520825-19-00 5 2025-12-16 IgAN is Primary Immunoglobulin A Nephropathy (IgAN) (also known as Ber
• Inhaled corticosteroids in young children with episodic wheezing: a multicenter cluster RCT Recruiting
  2025-522694-11-00 6 2025-12-12 Episodic expiratory wheezing
• A study to investigate the safety and efficacy of MEDI0618 compared to placebo in adult participants with episodic migraine Recruiting
  2024-512904-21-00 4 2025-12-10 Migraine
• A randomized, double-blinded, placebo-controlled trial to evaluate the efficacy and safety of ninerafaxstat in patients with symptomatic non … Recruiting
  2024-515125-28-00 4 2025-12-08 Non-obstructive hypertrophic cardiomyopathy
• First-in-Human Study of ALN-SNCA in Adult Participants with Early Parkinson’s Disease (PD) Recruiting
  2025-521431-37-00 1 2025-11-20 Parkinson's disease
• Research into the safety of a new agent (NRG5051) in healthy adults and patients with Parkinson's disease or ALS Recruiting
  2025-523872-22-00 1 2025-11-18 Parkinsons's Disease and amyotrophic lateral sclerosis (ALS)
• Pneumoccocal vaccine response in patients without a spleen, vaccinated before or after spleen removal. Recruiting
  2024-515363-63-00 6 2025-11-07 Asplenia
• Increasing the dosing interval of osimertinib in patients with EGFR mutated locally advanced or meta-static non-small cell lung cancer - OSI … Recruiting
  2024-514693-47-01 11 2025-10-28 EGFR mutated locally advanced or metastatic non-small cell lung cancer
• Research into the safety of a new agent (AX-5006) in people with and without Parkinson's disease. Recruiting
  2025-523254-14-00 1 2025-10-27 Parkinson's disease
• (Pre-BCGvacc) BCG vaccination: can pre-vaccination immune status predict outcome? Recruiting
  2024-514428-18-00 11 2025-10-24 health volunteerst
• An Open-label, Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumor/Aggressive Fibromatosis (DT/AF). Recruiting
  2024-515215-21-00 6 2025-10-24 DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF)
• C4951063: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine Recruiting
  2024-517121-10-00 5 2025-10-17 Menstrual Migraine
• Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting
  2024-516652-18-00 5 2025-10-10 Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
• A Study to Evaluate the Effect of TRIV-509 on Skin Barrier Function in Patients with Atopic Dermatitis. Recruiting
  2025-522635-34-00 3 2025-10-09 Atopic Dermatitis
• Study of zoldonrasib with or without daraxonrasib and other anticancer drugs in patients with RAS G12D-mutant non-small cell lung cancer (NS … Recruiting
  2025-521147-21-00 4 2025-10-08 Lung Cancer
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P

Showing 97–120 of 459 trials